Palivizumab in infants with gestational age ≤ 28 weeks and bronc̊hopulmonary dysplasia

Acta Biomedica de l'Ateneo Parmense

Volumn 72, Issue 5-6, 2001, Pages 109-113

  Parmigiani, Stefano ^a   Ubaldi, Alessandro ^a   Capuano, Ciro ^a   Massinissa Magini, Giulia ^a   Bianchi, Maria Edgarda ^a  

^a UNIVERSITY OF PARMA   (Italy)

Author keywords

Bronchopulmonary dysplasia; Gestational age 28 weeks; Infant; Palivizumab; Respiratory syncytial virus

Indexed keywords

ANTIBIOTIC AGENT; LUNG SURFACTANT EXTRACT; PALIVIZUMAB; PLACEBO; STEROID;

APNEA; ARTICLE; ARTIFICIAL VENTILATION; BRONCHIOLITIS; BRONCHOSPASM; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; CYANOSIS; DIARRHEA; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DYSPNEA; ECZEMA; EDEMA; FEEDING DISORDER; FEMALE; FEVER; GESTATIONAL AGE; HUMAN; INFANT; LUNG DYSPLASIA; MALE; NERVOUSNESS; NEWBORN INTENSIVE CARE; NONHUMAN; PROPHYLAXIS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RHINITIS; SIDE EFFECT; SNORING; VIRUS INFECTION; VOMITING;

ANALYSIS OF VARIANCE; ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; BIRTH WEIGHT; BRONCHOPULMONARY DYSPLASIA; CHI-SQUARE DISTRIBUTION; DATA INTERPRETATION, STATISTICAL; FEMALE; GESTATIONAL AGE; HUMANS; INFANT; INFANT, NEWBORN; INJECTIONS, INTRAMUSCULAR; INTERVIEWS; MALE; QUESTIONNAIRES; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; TIME FACTORS;

EID: 0035761495     PISSN: 03924203     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Grothuis J.R., Gutierrez K.M., Lauer B.A.: Respiratory syncytial virus infection in children with bronchopulmonary dysplasia. Pediatrics 1988; 82:199-203
2. Hall C.B.: Respiratory syncytial virus. In: Feigen R.D., Cherry D.I. (eds.): Textbook of Pediatric Infectious Diseses. Philadelphia, W.B. Saunders, 1998, p. 2084
3. Institute of Medicine Committee on Issues and Priorities for New Vaccine Development: Prospects for immunizing against respiratory syncytial virus. In: New Vaccine Development, Establishing Priorities. Washington, DC,: National Academy of Science Press 1988; 1:397-409
4. Johnson S., Oliver C., Prince G.A., et al.: Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus (RSV). J. Infect. Dis. 1997; 176:1215-1224
5. The IMPact-RSV Study Group: Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102:531-537
6. Zuccotti G.V., Giuffre L., Marini A., et al.: Immunoprofilassi dell'infezione da Virus Respiratorio Sinciziale (VRS) in lattanti ad alto rischio: impiego del palivizumab e sua tollerabilità. Riv. Ital. Pediatr. (IJP) 2000; 26:456-46